DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for Endometrial Clear Cell Adenocarcinoma — screening already-approved drugs against its 47-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEndometrial Clear Cell Adenocarcinoma maps to a 47-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for endometrial clear cell adenocarcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
fibroblast growth factor receptor 4 (FGFR4) — FGFR4 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 1~{r}drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8KH8 · 1.49 Å · ligand 1-[4-[(1~{R})-1-[3,5-bis(chloranyl)pyridin-4-yl]ethoxy]-5-cyano-pyridin-2-yl]-3-[6-methanoyl-5-[(4-methyl-2-oxidanylidene-piperazin-1-yl)methyl]-3-(2-morpholin-4-ylethoxy)pyridin-2-yl]urea (VVW). Experimental structure, not a prediction.
What the evidence adds up to
Twenty-two patients with clear cell adenocarcinoma of the endometrium treated at the University of North Carolina Memorial Hospital were older and had overall poorer survival than patients with non-clear cell endometrial adenocarcinoma. Stage I clear cell carcinoma patients, however, had a five-year survival similar to Stage I adenocarcinoma of the endometrium. Three additional cases were reported as a rare and aggressive type, with patients older and in menopause longer than typical endometrial carcinoma patients, possibly reflecting counterbalanced sex hormones in carcinogenesis.
A 2022 systematic review of laparoscopic surgery for clear cell endometrial carcinoma found only three studies, which were too diverse for meta-analysis. Minimally invasive surgery did not significantly influence progression-free or overall survival compared to laparotomy, but the authors state that more research is needed before the technique’s safety can be determined.
Two ovarian clear cell carcinoma cases with recurrent endometriosis were reported in 2023. Both patients had long-standing endometriosis and had undergone ovarian cyst removal for chocolate cysts that later recurred as clear cell carcinoma. One patient was stage IIB with P53 expression and survived one year after six cycles of TP regimen (platinum-containing chemotherapy). The other was stage IA and survived six years after the same six cycles. The authors note that radical surgery and postoperative platinum-containing chemotherapy are the primary treatment methods.
A separate 2023 report describes clear cell carcinoma of the ovary as a rare and aggressive subtype often associated with endometriosis, presenting unique diagnostic challenges because benign endometriotic tissue and malignant clear cell carcinoma can coexist in the same specimen. What is still missing are prospective trials large enough to compare surgical approaches for endometrial clear cell carcinoma, reliable biomarkers to stratify patients by risk of recurrence, and funding to move beyond small case series and retrospective reviews.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Cancer · 1979 · 43 citations
Clear cell carcinoma of the endometrium
AbstractThe clinical data of 22 patients with clear cell adenocarcinoma of the endometrium treated at the University of North Carolina Memorial Hospital are reported. In addition, the data with particular reference to survival, site of recurrence, and treatment are combined with information from two previous reports of clear cell adenocarcinoma of the endometrium to better define survival. It is noted that the patients with clear cell adenocarcinoma of the endometrium were older and had an overall poorer survival than is reported for adenocarcinoma of the endometrium (nonclear cell). Patients with Stage I clear cell carcinoma of the endometrium, however, had a similar five-year survival to Stage I adenocarcinoma of the endometrium. The paper also examines treatment methods and correlates these with site of recurrence as well as survival.
AbstractThree cases of clear cell carcinoma of the endometrium are here reported. Clear cell carcinoma is a rare and aggressive type of endometrial adenocarcinoma. Patients are older and are in the menopause much longer than are patients with typical endometrial carcinoma. This fact may reflect the presence of counterbalanced sex hormones in the process of carcinogenesis.
International Journal of Women s Health · 2023 · 1 citations · open access
Case Series and a Literature Review: Two Ovarian Clear Cell Carcinoma Cases with Recurrent Endometriosis
AbstractIntroduction: Endometriosis-associated ovarian cancer (EAOC) is rare, occurring approximately in 1% of women with ovarian endometriosis. The main histological types are endometrioid adenocarcinoma and clear cell carcinoma (CCC), with the latter being the least common. Case Presentation: In our hospital, we recently summarized two patients with ovarian clear cell carcinoma with similar characteristics. They all had endometriosis for a long time and had undergone ovarian cyst removal due to a chocolate cyst. Unfortunately, the cyst recurred after surgery, and the histological diagnosis was clear cell carcinoma. In case 1, the expression of P53 was found in the tumor by regular examination, and the stage was IIB. In Case 2, we found it in intraoperative freezing; the stage was IA. Case 1 has been treated with the TP regimen six times, and the survival period has reached one year. Case 2 had a survival period of 6 years after completing six TP regimen treatments. Clinicians should pay attention to patients with a long history of endometriosis and postoperative recurrence of ovarian cysts accompanied by serum CA-125 of more than 200U/mL. Imaging examination has a good prospect in diagnosing malignant transformation of endometriosis, especially PET-CT. Conclusion: This case report highlights the risk factors related to the formation of ovarian clear cell carcinoma and suggests that the follow-up of patients with ovarian endometriosis is essential because of its recurrence characteristics. Radical surgery and postoperative platinum-containing chemotherapy are the primary treatment methods at present.
World Journal of Clinical Oncology · 2020 · 1 citations · open access
Endometrial clear cell carcinoma invading the right oviduct with a cooccurring ipsilateral oviduct adenomatoid tumor: A case report
AbstractBACKGROUND: To investigate the clinicopathological features of endometrial clear cell carcinoma that has invaded the right oviduct with a cooccurring ipsilateral oviduct adenomatoid tumor. CASE SUMMARY: A case of endometrial clear cell carcinoma invading the right oviduct with a cooccurring ipsilateral oviduct adenomatoid tumor was collected and analyzed using pathomorphology and immunohistochemistry. Endometrial clear cell carcinoma cells were distributed in a solid nest, papillary, shoe nail-like, and glandular tube-like distribution. There was infiltrative growth, and tumor cells had clear cytoplasm and obvious nuclear heteromorphism. The cancer tissue was necrotic and mitotic. The cancer tissue invaded the right oviduct. The ipsilateral oviduct also had an adenomatoid tumor. The adenomatoid tumor was arranged in microcapsules lined with flat or cubic cells that were surrounded by smooth muscle tissue. The adenomatoid tumor cells were round in shape. CONCLUSION: Clear cell carcinoma of the endometrium can invade the oviduct and occur simultaneously with tubal adenomatoid tumors. Upon pathological diagnosis, one should pay close attention to distinguishing whether an endometrial clear cell carcinoma is invading the oviduct or whether it is accompanied by an adenomatoid tumor of the oviduct. Immunohistochemistry is helpful to differentiate these two disease entities. Endometrial clear cell carcinomas express Napsin-A and P16 and are negative for estrogen receptor and progesterone receptor. The presence of endometrial clear cell carcinoma does not affect the expression of CK and calretinin in adenomatoid tumors.
Carcinomul cu celule clare dezvoltat pe chist ovarian endometriozic
AbstractClear cell carcinoma of the ovary is a rare and aggressive subtype of ovarian cancer. It is often associated with endometriosis, a chronic condition characterized by the presence of endometrial-like tissue outside the uterus. Clear cell carcinoma arising within the context of endometriosis presents unique diagnostic challenges for pathologists. The coexistence of benign endometriotic tissue and malignant clear cell carcinoma in the same specimen can be confounding.
Hellenic Journal of Obstetrics and Gynecology · 2022 · 0 citations · open access
Laparoscopic surgery for clear cell endometrial carcinoma, is it a realistic approach?
AbstractClear cell endometrial carcinoma is an aggressive form of endometrial cancer that has a poor prognosis for survival. Over the past ten years, laparoscopic surgery has replaced open surgery as the preferred method of treating early-stage endometrial cancer. However, its effect on the prognosis of patients with clear cell carcinoma is still unclear. In the current systematic review, we examined the information that was published in the following databases: Medline, Scopus, Clinicaltrials.gov, EMBASE, Cochrane Central Register of Controlled Trials, CENTRAL, and Google Scholar. Three studies were found to be significantly diverse; as a result, meta-analysis was not possible. Current research reveals that compared to traditional laparotomy, minimally invasive surgery does not significantly influence progression-free and overall survival rates; nevertheless, given the relative dearth of data, more research is required before the technique’s safety can be determined.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
